Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434473 · ClinicalTrials.gov registry record · Phase 2
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00434473 is a Phase 2 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00434473, a Phase 2 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study will be conducted at 15-20 US centers in a randomized, placebo-controlled, double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC), fever (T ≥38.0°C) and serum sPLA2 concentration ≥50 ng/mL.
Interventions
- OTHER Placebo
- DRUG A-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00434473
The ClinicalTrials.gov registry entry for NCT00434473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00434473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00434473 about?
NCT00434473 is a clinical study titled "IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome". The study will be conducted at 15-20 US centers in a randomized, placebo-controlled, double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC), fever (T ≥38.0°C) and serum sPLA2 ...
What is the current status of trial NCT00434473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00434473?
The interventions under investigation include: Placebo (OTHER), A-001 (DRUG).
Who is sponsoring clinical trial NCT00434473?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.